Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen : Federal Circuit Emphasizes High Bar For Enablement Of Functional Claims

07/29/2021 | 10:47pm EDT

In two recent decisions in Amgen Inc. v. Sanofi, Aventisub LLC, the Federal Circuit has made clear that broad functional patent claims must be fully enabled and underscored the high bar for enablement of broad biological compound claims including functional limitations. Amgen v. Sanofi, Aventisub LLC, 987 F.3d 1080 (Fed. Cir. 2021). On June 21, the Federal Circuit denied Amgen's petition for rehearing en banc, and the original panel authored an opinion responding to Amgen and the amicis' concerns that the court's decision created a new enablement test or eviscerated genus claims. Amgen Inc. v. Sanofi, Aventisub LLC, No. 20-1074, 2021 WL 2525530 (Fed. Cir. June 21, 2021). Patentees claiming biological materials should be aware that "[e]nablement is required, even for generic claims to biological materials[,]" and "as with genus claims to chemical compounds, if they encompass more subject matter than just a few species, they need to be enabled accordingly." Id. at *1. Further, "[b]iological compositions not actually prepared need to be described constructively, if required to enable the full scope of the claims, with procedures and names of resultant compositions, as with chemical compositions." Id.

Amgen's patent claims are directed to monoclonal antibodies that bind to the PCSK9 enzyme and block PCSK9 binding to LDL receptors to lower LDL cholesterol. Amgen, 987 F.3d at 1083. The claims recite that when bound to the enzyme, the claimed antibody binds to one or more of several identified amino acid residues, ultimately blocking the enzyme's ability to bind to the LDL receptor. Id. An exemplary claim recites:

  1. An isolated monoclonal antibody, wherein, when bound to PCSK9, the monoclonal antibody binds to at least one of the following residues: S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO:3, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR.

Id.

A jury twice found Amgen's claims enabled, but the district court granted Sanofi's motion for judgment as a matter of law ("JMOL") that the claims were not enabled, due to the breadth of the claims and their functional nature. Id. at 1083-84, 1086.

The Federal Circuit affirmed the district court's grant of JMOL, instructing that for biological claims that include functional requirements, courts must look to the breadth of the functionality, especially in unpredictable fields or where the patent includes less instruction on how to make the invention. Id. at 1086. The Federal Circuit cautioned that "[w]hile functional claim limitations are not necessarily precluded in claims that meet the enablement requirement, such limitations pose high hurdles in fulfilling the enablement requirement for claims with broad functional language." Id. at 1087. The Court noted that the antibody claims at issue in the appeal were defined by their function: binding to combinations of sites (residues) on the PCSK9 protein and blocking the PCSK9/LDLR interaction. Id. Applying the Wands factors, the Federal Circuit affirmed the district court's findings that Amgen's claims were broad-particularly, broader in functional diversity than the disclosed examples-the field was unpredictable, the specification's guidance and working examples were not directed to the full scope of the claims, and significant experimentation would be necessary to make other embodiments within the claim scope. Id. at 1084, 1087-88 (citing In re Wands, 858 F.2d 731 (Fed. Cir. 1988)).

In its original opinion, the panel briefly addressed Amgen's concern that the court's decision would overrule Wands, ultimately disagreeing, reasoning that the facts evidenced a vast range of potential embodiments outside the disclosed antibody examples that could meet the claims' functional limitations. Id. at 1088. Amgen petitioned for rehearing en banc, and with the Federal Circuit's denial, the panel issued a decision reiterating that it did not create a new test for enablement, but instead followed the longstanding requirement that genus claims must be enabled by a disclosure commensurate in scope to the claim scope. Amgen, 2021 WL 2525530, at *1. The Court explained that the purpose of the enablement requirement is to prevent patentees from claiming a broad genus that they have not invented, reasoning that claims to a non-enabled genus would suppress innovation. Id. at *2. The Court did note that functional claim limitations render it particularly difficult to ascertain whether a species falls within the scope of a genus claim, explaining the high bar for enablement of claims including these limitations. Id. at *3.

The Federal Circuit denied that its opinion spelled the death of genus claims, asserting that biological genus claims could be allowable if examples across the full scope of the claim are disclosed either actually or constructively. Id. at *1. In its opinion, the Court explained that, "as with chemical compositions," patentees should constructively describe claimed biological compositions across the claim scope "with procedures and names of resultant compositions" when the claims reach beyond compounds actually reduced to practice, although the Court did not explain concretely what would constitute an adequate constructive description of an antibody claim. Id.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Ms Maria Stubbings
Perkins Coie LLP
700 13th Street, NW
Suite 800
Washington, DC
20005-3960
UNITED STATES

© Mondaq Ltd, 2021 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

Stocks mentioned in the article
ChangeLast1st jan.
AMGEN INC. -0.23% 213.11 Delayed Quote.-7.09%
SANOFI 0.12% 82.12 Real-time Quote.4.22%
All news about AMGEN INC.
01:12pAMGEN : Exploring Climate Change and Lung Health
PU
04:54aAMGEN : Secures FDA's Approval for Repatha in Heterozygous Familial Hypercholesterolemia
MT
09/24Amgen Announces U.S. Food and Drug Administration Approves Repatha in Pediatric Patient..
CI
09/24AMGEN : FDA Approves Repatha« (evolocumab) In Pediatric Patients Age 10 And Older With Het..
PR
09/24FDA APPROVES AMGEN'S REPATHA AS ADD- : Bloomberg
MT
09/24Amplitude Healthcare Acquisition Corporation announced that it has received $100 millio..
CI
09/23WALL STREET STOCK EXCHANGE : As smooth as silk
09/23AMGEN : Daiwa Securities Downgrades Amgen to Neutral From Outperform, Price Target at $220
MT
09/23ANALYST RECOMMENDATIONS : Amgen, Apple, AstraZeneca, FedEx, T-Mobile US...
09/22AMGEN : To Present At The 2021 Cantor Global Healthcare Conference
PR
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2021 26 047 M - -
Net income 2021 6 027 M - -
Net Debt 2021 22 255 M - -
P/E ratio 2021 21,1x
Yield 2021 3,25%
Capitalization 121 B 121 B -
EV / Sales 2021 5,50x
EV / Sales 2022 5,17x
Nbr of Employees 24 300
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 213,61 $
Average target price 243,90 $
Spread / Average Target 14,2%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.-7.09%121 299
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.19.37%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037